Академический Документы
Профессиональный Документы
Культура Документы
parenteral nutrition with proteins and glucose alone led to poor growth and altered visual
functions compared to PN+n-6 fatty acids emphasizing the importance of EFA.
All EFA are not same:There are important differences between Omega 6 and Omega 3 fatty acids and some of
the differences are very important from clinical point of view.
Omega 6 LCPUFA (Eicosanoids) are more potent, are proinflammatory and
adipogenic
Omegas 3 LCPUFA (Eicosanoids) on the other hand are anti inflammatory and
decreases fat deposition. Fish oil (EPA & DHA) has been used in Rheumatoid
arthritis emphasizing its anti inflammatory properties. There are various
differences between EPA and DHA as well. DHA has been shown to prevent CVS
disease by reducing blood vessel inflammation and atherosclerosis 1.There are less
heart diseases in Eskimos and Japanese fisherman which has been attributed to
higher blood DHA/EPA levels c.f. Omega 6 LCPUFA in them. Triglyceride levels
fall more with 26% in DHA (26%) compared to EPA (21%). So evidence is in
favor of DHA compared to EPA for the beneficial effects seen with Omega 3 fatty
acids. More over EPA concentration in mothers milk in negligible making its
importance very doubtful in infant nutrition.
5-10:1
30-70:1
12:1
2:1
The main reason for poor Omega 3 FA in Indian diet is lack of animal products especially
fish and excess intake of animal milk and milk products. There are a number of vegetable
sources of EFA and one must have knowledge so that the same can be advised to the
mother.
Flaxseed or linseed
Sunflower
Rapeseed or canola
Safflower
Peanut
Sesame
Olive
Palmolive
Perilla
Corn
Walnut
Primrose
Soya
Borage
Invisible fats
All infants should be fed on exclusive mothers milk for first six months and in
case mothers milk is not sufficient, alternative milk with sufficient amounts of EFA
should be provided. As unmodified bovine milk (cow or buffalo or goat) does not contain
any EFA, the only option is a balanced infant formula with ratio of LA/ALA between5:1
to 15:1.
DHA supplementation in term formula:Cochrane (2001) reviews after analyzing 10 trials have concluded that there are
contradictory results on beneficial effects on developmental indices. Certain trials show
better problem solving (finding a hidden toy) 3 or higher scores on Bayley Mental
Development Index until 17 weeks of age4 while others show no benefits5 / Transient
benefit6 There is some effect seen in reduction of BP and Type I DM with no documented
side effects.
LCPUFA and preterm formula:There is no ambiguity as far as preterm milk formula and their supplementation is
concerned. Meta analysis by San Giovanni show better visual acuity at 2&4 months.
There is strong recommendation by AAP that preterm formulae should contain both AA
and DHA.
Infant nutrition 6months to one year:Recommendations for fat intake
First 6 months
40-60% of total energy
Omega 6: omega 3 ratio 5-10:1
<1% trans fats
After 2 yrs
Fat 30-35% calories
Omega 6: 4-10% energy
Omega 3: 1-2% energy
Transfats <2% energy
Infants must be continued breast milk or term baby follow-up formula along with
addition of semisolid diet with emphasis on addition of vegetable oils with high Omega 3
FA (Soyabean oil, canola oil, mustard oil, fish oil, rapseed oil etc.)
Prime Key Messages:Essential fatty acids are important for brain, retina and growth
All essential fatty acids are not same
Omega 3 LCPUFA have anti allergic properties, good for brain and heart
Maternal diet should contain enough DHA, otherwise supplementation is a good
idea
Supplementation during lactation is less rewarding
Breast feeds till 6 months is best strategy
If not
Cows milk is absolutely no
Term baby formulae is second best option
Preterm formulae should be supplemented with DHA
For infants and bigger children: fat content should come down, DHA still
important
References:
1. Grimble RF. Dietary lipids and the inflammatory response. Proceedings of the
Nutrition Society 1998; 57:535-542.
2. Helland. Pediatrics 2003; 111(1): e 39-440.
3. Williatts P. Lancet 1998; 352:688-91)
4. Birch EE.Dev Med Child Neurol 2000; 42:174-81)
5. Makrides M. Pediatrics 2000; 105:32-38.
6. Carlson SE. J Pediatr 1992; 120:S159-67.
Marketed by:SIROY
LIFE SCIENCES
TOLL FREE NO-1800-1234-989
Mob: - +91 9810754691
Mail info@siroylifesciences.com
www.siroylifesciences.com